Navigation Links
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Date:6/5/2008

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics, Inc. (TFT). NF-kB Transcription Factor Decoy inhibits NF-kappa B, a protein implicated in the inflammatory cascade in diseases such as inflammatory bowel disease (IBD), eczema, rheumatoid arthritis, and asthma.

Under the terms of the agreement, Anesiva will receive an upfront license fee, with additional payments dependent on development and regulatory milestones potentially totaling up to $114 million if two products are commercialized. Anesiva would also be entitled to royalty payments upon successful commercialization of any drug candidate(s). Additional terms were not disclosed. TFT will be responsible for the future development of Avrina(TM), and intellectual property associated with the NF-kB Decoy program will be transferred to TFT.

"Anesiva considers TFT a capable development organization to move this program forward," said John P. McLaughlin, chief executive officer of Anesiva. "With a strong focus on anti-inflammatory transcription factor decoys, we believe that TFT is well positioned to advance the NF-kappa B program, which holds great potential to impact the treatment of inflammatory diseases."

TFT initially plans to take Avrina(TM), a highly potent and selective inhibitor of NF-kappa B, into clinical trials in IBD in 2009. Avrina has shown highly encouraging results in multiple preclinical models of both Crohn's Disease and ulcerative colitis, two forms of IBD. These results have been well received in international sc
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces First Quarter 2008 Financial Results
2. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
3. Anesiva Announces Expansion of Zingo Agreement in Europe
4. Anesiva Announces New Zingo Marketing and Distribution Agreement
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
7. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
8. Anesiva Appoints Daniel Janney to Board of Directors
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Announces Completion of Common Stock Offering
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... Long Beach, CA (PRWEB) December 17, 2014 ... Technology, Inc. to provide a larger packaged waste water ... district in King Abdullah Economic City (KAEC). Two years ... for EMAAR’s Jeddah Gate Development, serving two residential towers ... plant capacity is over a quarter million gallons per ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... Cholesterol Test Can Help Identify Patients At Risk of Heart ... ... Atherotech, Inc., a,cardio-diagnostic company, today announced that the largest private,insurers in ... (FEHB) Program now cover the VAP(R) (Vertical Auto Profile),Test, the most ...
... (OTC Bulletin Board: CDXC) a leader in phytochemical ... for the,second quarter of 2008. On a reported ... Principles (GAAP), ChromaDex announced a,net loss attributable to ... months ended June 28, 2008., As of ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS , ... and oncology, announced today the appointment of Prof. ... effective as of September 1,2008. Prof. Engel is ... AEterna Zentaris. He succeeds Juergen Ernst, who had,been ...
Cached Biology Technology:VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured 2ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO 2AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO 3
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... (February 10, 2010) New research from the Monell Center ... to both a family history of alcoholism and the child,s ... how liking for sweets differs among children based on underlying ... is rewarding to all kids and makes them feel good," ...
... Davis, study by a top ecological,forecaster says it is ... Earth,s natural systems will occur -- a worrisome,finding for ... climate change into an irreparable global disaster. "Many ... sudden,changes in natural systems, in hopes of forestalling those ...
... don,t swallow the worm at the bottom of a bottle ... of the potent Mexican liquor, according to scientists at the ... Institute of Ontario (BIO) have discovered that mescal itself contains ... tasty "worm" that many avoid consuming. Their findings will appear ...
Cached Biology News:Intense sweets taste especially good to some kids 2New UC Davis study: Climate 'tipping points' may arrive without warning, says top forecaster 2Mescal 'worm' test shows DNA leaks into preservatives 2
...
...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
Biology Products: